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Abstract
Introduction Although the nature of basal ganglia hypere-
chogenicity in transcranial sonography (TCS) examinations
remains unclear, many studies have shown associations be-
tween hyperechogenicity and iron accumulation. The role
of iron in basal ganglia hyperechogenicity raises interest in
the use of TCS in forms of neurodegeneration with brain
iron accumulation (NBIA). Here we analyzed TCS and
magnetic resonance imaging (MRI) findings among patients
affected by one type of NBIA, mitochondrial membrane
protein-associated neurodegeneration (MPAN).
Methods Investigations using MRI and TCS were per-
formed on 13 patients exhibiting a C19orf12 gene muta-
tion.
Results The use of T2/T2* MRI revealed hypointense le-
sions restricted to the globus pallidus and substantia nigra.
Using TCS examination, 12 patients exhibited bilateral hy-
perechogenicity of the lenticular nucleus, while no patients
showed substantia nigra hyperechogenicity.
Conclusion Investigations with TCS revealed a distinctive
hyperechogenicity pattern of the basal ganglia in MPAN
patients, which might be useful for differential diagnostics.
The variable TCS imaging findings in NBIA patients may
result from the presence of different iron content, iron bind-
ing partners, such as ferritin and neuromelanin, as well as
structural changes, such as gliosis.
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Introduction
Transcranial sonography (TCS) is a simple and safe tech-
nique that appears to be useful in evaluating and diagnosing
various neurodegenerative disorders. It is employed as an
additional tool for diagnosing idiopathic Parkinson’s dis-
ease (PD), since substantia nigra (SN) hyperechogenicity
is detectable in approximately 90% of patients even in the
very early clinical stages of PD [1]. TCS is also presently
considered an additional diagnostic tool for corticobasal de-
generation (CBD), Wilson’s disease (WD), primary restless
legs syndrome (RLS) [2–4] and multiple sclerosis (MS)
progression [5]. This technique can detect hyperechogenic-
ity of midbrain structures, including the thalamus, lenticular
nucleus (LN), and caudate nucleus, and can be used to de-
termine the diameter of the third ventricle or the frontal horn
of the lateral ventricle [2]. The exact nature of basal ganglia
hyperechogenicity is unclear, but many post-mortem and
animal studies show associations between hyperechogenic-
ity and iron and/or other ion accumulation diseases [6–8].
This potential role of iron in basal ganglia hyperechogenic-
ity raises great interest in the TCS findings in cases of
neurodegeneration with brain iron accumulation (NBIA).
The NBIAs are a group of genetic conditions characterized
by a progressive hypokinetic and/or hyperkinetic movement
disorder along with excessive iron deposition in the brain,
particularly in the globus pallidus (GP) and SN [9]. The
major known forms of NBIA are pantothenate kinase-as-
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sociated neurodegeneration (PKAN), PLA2G6-associated
neurodegeneration (PLAN) and now mitochondrial mem-
brane protein-associated neurodegeneration (MPAN). The
PKAN is caused by mutation of the pantothenate kinase 2
(PANK2) gene and accounts for about half of all NBIAs
[10]. The MPAN was recently found, accounts for a sub-
stantial number of NBIA cases [11–13], and is caused by
a mutation in the orphan gene C19orf12, which encodes
a mitochondrial protein. The role of C19orf12 remains un-
known, but is likely that C19orf12 is involved in the same
metabolic pathway implicated in PKAN and PLAN, essen-
tial mitochondrial function [14], coenzyme A metabolism
and impaired lipid and myelin synthesis [15, 16]. The clin-
ical progression of MPAN is similar to that of classical
PKAN, but with a later age of onset and milder symptoms
[11, 17, 18]. In the present study, we investigated MRI fea-
tures and TSC findings among 13 patients with confirmed
MPAN.
Methods
This study included 13 patients with a mutation in the
orphan gene C19orf12. Of these patients, 10 carried the
homozygous deletion c.204_214del11 (Gly69ArgfsX10)
in both alleles, and 3 carried the deletion in combina-
tion with different missense mutations (p.Gly53Arg, and
p.Thr11Met) in the compound heterozygous state. All in-
cluded patients gave their written informed consent to
participate. Patient medical histories, previous and current
therapies, and demographic data were recorded. All pa-
tients underwent a neurological examination and MRI and
TCS were performed on the same day.
Magnetic resonance imaging was performed using a 1.5-
T scanner (Philips Achieva, Eindhoven, the Netherlands).
T1-weighted (TR = 596 ms, TE = 15 ms) and T2-weighted
(TR = 6783 ms, TE = 140 ms) images were acquired in axial
planes with 5-mm slice thickness. Gradient echo T2* im-
ages were obtained as a single-echo sequence (TR = 693 ms,
TE = 23 ms, flip angle = 20°).
TCS was performed by a sonographer (MS) who was
blinded to the MRI results and specific clinical diagnosis,
through the preauricular acoustic bone window, using a 2.5-
MHz phased-array transducer (Vivid 7, Milwaukee, WI).
The chosen ultrasound parameters were a penetration depth
of 14–16 cm, and a dynamic range of 50 dB. Image con-
trast and brightness were adjusted to obtain the best image.
The SN echogenic size measurements were performed auto-
matically on axial TCS scans after manually encircling the
outer circumference of the SN echogenic area. For the ultra-
sound system used SN echogenic areas of ≥0.25 cm2 were
considered hyperechogenic, those 0.20 cm2 were consid-
ered normal, and intermediate sized areas were considered
moderately hyperechogenic. The LN and thalami were vi-
sualized in the third ventricular plane. The echogenicity of
the LN and thalami were classified as hyperechogenic when
their echogenicity was more intense than the surrounding
white matter. The area of hyperechogenicity was measured
by manually encircling the outer circumference of the hy-
perechogenic area. The width of the third ventricle was
measured on the axial scanning plane.
The control group comprised 18 adult patients with-
out neurological symptoms, including 11 women, and with
a mean age of 47 years (range 20–73 years). All control
patients had normal MRI results. The control group was
not age matched with the patients, but iron accumulation
increases in the normally aging brain [18, 19], and we can
assume that any changes would be more prominent with
time. None showed bilateral LN changes, although four
showed unilateral LN changes. None showed changes in
the thalami. LN hyperechogenicity was found previously
in healthy individuals, but had no prognostic value, and
no follow-up studies were conducted [20]. As LN hypere-
chogenicity was found only in 4 controls and only unilat-
erally there was no correlation made with the study group.
Statistical analysis was performed to investigate the re-
lationship between age and disease duration and LN hyper-
echogenicity. A generalized linear model (GLM) [21] was
chosen as the basic model to compare LN hyperechogenic-
ity among patients. Since the study design involved record-
ing two measurements for both sides, we also included the
factor “side” in the model. An optimal model comprising
the Gaussian error and the log-link function was chosen
from the GLM family based on the Akaike Information Cri-
terion (AIC), and the deviance was examined to ascertain
whether the model was sufficient. The calculations were
performed using SAS system rel.13.2, p value of <0.05
was considered to indicate statistical significance.
Results
In this study 13 young adults (2 females, 11 males) of
Polish Caucasian origin were investigated, 1 patient (no. 10)
was born to related parents and 3 patients (nos. 2, 6, and
11) were brothers who had 2 healthy siblings. There was
no family history of affected relatives. All patients were
born after a normal pregnancy and were assessed for 9 or
10 points on the Apgar scale.
Table 1 presents the patients’ demographic and clini-
cal data. The mean age of onset was 8.5 years (range
3–15 years) and the time between first symptoms and the
present study was 13 years (range 8–23 years). Of the pa-
tients 12 had spastic paraparesis of the lower extremities,
including 5 who had tetraparesis with the lower limbs be-
ing far more affected, 10 patients had dysarthria, and 10
K
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Fig. 1 Magnetic resonance
imaging results from MPAN
patient. a and b T2-weighted
images, c and d T2*-weighted
images. The hypointense signal
in globus pallidus (a and c) and
substantia nigra (b and d) is
due to iron accumulation. The
third ventricle is indicated by
a vertical arrow. Notice a medial
medullary lamina between the
internal and external part of
the GP in T2-weighted images
– a radiological phenomenon
typical for MPAN patients (red
arrow). Hypointense signal in
SN is often less prominent than
in GP (blue arrow)










P.9 P.10 P.11 P.12 P.13
SN (r) 0.19 0.14 0.10 0.11 0.18 0.17 0.13 0.2 0.15 0.12 0.16 0.23 0.16 0.2
SN (l) 0.19 0.11 0.15 0.14 0.12 0.19 0.15 0.2 0.13 0.13 0.17 0.17 0.19 0.2
LN (r) 1.22 1.24 0.80 0.41 0.76 0.48 0.47 – 0.46 0.65 0.37 0.56 0.77 0.9




– – – – – – – – – – – – – –
Third ventricle
diameter (mm)
5.8 2.4 2.2 2.7 2.2 1.5 2.5 9.0 9.8 3.1 3.0 2.9 6.2 5.0
MPAN mitochondrial membrane protein-associated neurodegeneration, TCS transcranial sonography, SN substantia nigra, LN lenticular nucleus
had optic nerve atrophy. Of the 13 included cases, 3 showed
parkinsonism and 7 showed dystonia, 3 patients had psychi-
atric symptoms, 1 of which was diagnosed with schizophre-
nia and 2 with obsessive-compulsive behavior and all of
whom were treated with neuroleptics.
In all 13 cases, the T2-weighted and T2* images of the
brain showed low signal intensity in the GP and SN bilater-
ally (Fig. 1). Our results showed no other MRI hypointen-
sity typical of iron accumulation.
All patients had a sufficient bone window for TCS. The
results of TCS revealed changes restricted to the medial
LN, corresponding to the anatomical area of the GP (Ta-
ble 2; Fig. 2d). Of the patients 12 exhibited symmetrical
hyperechogenicity of the LN. Patient number 8 showed
K
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Fig. 2 Imaging results from
Patient 4. a and b, T2* MRI
images of the substantia nigra
(a) and globus pallidus (b). The
third ventricle is indicated by a
vertical arrow. c and d, Corre-
sponding transcranial sonogra-
phy images. The substantia nigra
is indicated by an blue arrow (c).
The area of hyperechogenicity is
outlined in the medial lenticular
nucleus, corresponding to the
anatomical globus pallidus (d) –
red arrow
no changes in the LN, but had an increased third ventri-
cle diameter. At the follow-up visit after 1 year, TCS ex-
amination revealed LN hyperechogenicity in this patient.
One case showed moderate hyperechogenicity of the right
SN, other patients had normal SN echogenicity (Table 2;
Fig. 2c). There was no LN hyperechogenicity area depen-
dency with age, symptom duration (Fig. 3), and clinical
phenotype (data not presented).
Discussion
The NBIA patients have characteristic MRI findings, in-
cluding hypointense signals on T2 and T2* images due to
iron accumulation [9, 18, 22]. Our present MRI findings in
MPAN patients showed T2/T2*WI hypointensity in the GP
and SN, which is the pattern consistently reported by previ-
ous MRI studies in MPAN patients. As in the literature, our
MPAN patients showed no involvement of other subcortical
structures, such as the putamen, caudate nucleus, thalamus,
dentate nucleus, or cortex [11, 12].
No typical pattern has been identified for TCS results in
NBIA patients. Our study revealed LN hyperechogenicity
corresponding to the GP hypointensity shown in MRI. None
of our patients showed SN hyperechogenicity in TCS, de-
spite SN hypointensity on MRIs. We found similar results
in a prior study of only three patients [23]. The patient
who showed no LN hyperechogenicity in the preliminary
study was also patient 8 in our current study, and in this
study he showed TCS results typical for MPAN patients.
Since the TCS results changed over time in this patient, we
speculated that TCS results might be impacted by the dura-
tion of the clinical symptoms and/or the patient’s age. Our
present analysis showed that LN hyperechogenicity area
was not correlated with patient age or symptom duration;
however, a limitation of this analysis was that it included
only a small group of adult patients, all of whom had ex-
perienced symptoms for a few years, and no patients with
very recent onset of symptoms. There are no data avail-
able of presymptomatic MPAN patients and no conclusions
can be drawn when TCS changes can be detected in the
disease course. Interestingly, none of our patients showed
SN hyperechogenicity in TCS, even though all had obvious
changes in MRI. The exact nature of TCS hyperechogenic-
ity in neurodegenerative diseases is not yet understood. Pre-
vious studies suggest a correlation with metal accumula-
tion [1–7, 24], which is supported by evidence from post-
mortem studies [6, 8]. Among MPAN patients, we would
expect TCS hyperechogenicity in both the LN and SN. Kos-
tic et al. performed TCS in patients with PKAN, and found
that all patients showed hyperechogenicity in both the SN
and LN [25]. On the other hand, Liman et al. examined
seven patients with NBIA (including three with confirmed
PKAN) and found SN hyperechogenicity in all patients,
with no changes in the LN [26]. In an investigation of
patients with late-onset NBIA with parkinsonism, Brugge-
K
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Fig. 3 GLM models show-
ing no dependency of LN
echogenicity on age (a), symp-
toms duration (b). To find the
impact of age or symptoms du-
ration patients were divided into
3 groups depending on age (a)
or symptoms duration (b) – the
intervals are given in square
brackets. a LN echogenicity de-
creases when comparing the
youngest patients to “mid-
dle-age” ones (age 18 years
comparing to age 20 to 22 years)
and then is stable for the oldest
group (23 to 31 years) com-
paring to “middle-age”, but the
changes are not significant. b
LN echgenicity is stable for first
2 intervals (symptoms duration
from 8 to 10 years to symptoms
duration from 12 to 14 years)
and in the last group with the
longest symptoms duration (16
to 23 years) it rises, but the
changes are not significant
mann et al. found that one patient showed typical MRI find-
ings, along with TCS results of LN hyperechogenicity and
normal SN, while genetic tests showed no mutation [27].
Bruggemann et al. also conducted a study within a family
carrying a mutation in the ATP13A2 gene that is responsible
for Kufor-Rakeb syndrome, and showed that the single het-
erozygous mutation was associated with parkinsonism, but
that all mutation carriers showed normal SN echogenicity
[28].
In accordance with our present TCS findings, post-
mortem analysis of an MPAN patient with a C19orf12
mutation revealed widespread iron deposits in the GP and
K
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minimal iron deposition in the SN [10]; however, TCS
results vary among different NBIA syndromes despite ob-
vious iron accumulation and similar MRI features regarding
GP and SN hypointensity in T2/T2*. Thus, it is possible
that hyperechogenicity is influenced not only by metal
ions themselves, but also different iron binding partners,
such as neuromelanin and ferritin content, which might
differ among NBIA patients [7]. Experimental studies in
an animal model of PD show that SN hyperechogenicity is
caused by structural changes, such as gliosis, rather than by
increased iron concentration [29]. Finally, only one of our
patients had increased diameter of the third ventricle. This
phenomenon is correlated with midbrain structure atrophy
and is used for TCS differential diagnosis for progressive
supranuclear palsy (PSP) [30]. Brain atrophy is not typical
for MPAN patients and was present only in patient no. 8.
Together with different LN hyperechogenicity results it
suggests slightly different disease course in this case.
The study has some limitations. Firstly, a small study
group might be the reason that we failed to show corre-
lations between TCS echogenicity and clinical symptoms.
Secondly, the control group was not age matched with pa-
tients, but it is unlikely that it influenced the results.
Conclusion
The use of TCS may be useful for making a differential
diagnosis in NBIA patients, but not for primary diagnosis.
In particular, TCS can be employed to distinguish between
PKAN and MPAN. The variable TCS results among NBIA
patients are likely due to different pathomechanisms of iron
deposit accumulation/formation and TSC hyperechogenic-
ity is more correlated with metal-binding compounds, in-
flammation, and demyelination than with metal accumula-
tion.
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